Immunotherapy Now Standard for Some Patients With CRC

With recent approvals of pembrolizumab and nivolumab for the treatment of refractory deficient mismatch repair (dMMR) metastatic colorectal cancer (CRC), immunotherapy has made its way into the field of gastrointestinal oncology. Many questions remain, however, including optimal approaches to dMMR cancers and reasons for a lack of efficacy seen in proficient MMR (pMMR) CRC. Experts discussed these issues and the management of immunotherapy … (leggi tutto)